Organization: YM Biosciences Inc

AvidBiologics completes VC financing round

Toronto-based AvidBiologics Inc has closed a financing round to move its antibody-drug conjugate (ADC) technologies into clinical trials. The privately held firm — a 2011 spinout from YM BioSciences Inc — secured an unspecified amount of financing from Lumira Capital (lead), MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and the company’s founding investors.…

YM Bioscience purchased by CA-based Gilead Sciences

Mississauga ON-based YM Biosciences Inc is being acquired by Gilead Sciences Inc, Foster City CA, for $510 million — the latest promising Canadian biotech firm to be purchased by a foreign buyer. Founded in 1994, YM Biosciences has developed CYT387, a therapeutic treatment for myelofibrosis — a progressive chronic bone disorder — and has reported…

YM Biosciences concludes $23-million financing

YM Biosciences Inc has concluded a bought financing deal for gross proceeds of $23 million. The Mississauga ON-based firm will receive the financing from a syndicate led by Dundee Securities Corp and including Canaccord Capital Corp, Dlouhy Merchant Group and Haywood Securities. The proceeds will be used primarily to finance pivotal Phase III clinical trials…

YM Biosciences issues $15-million floatation

YM Biosciences Inc has raised $15 million with the floatation of 3.75 million shares on the Toronto Stock Exchange and the Alternative Investment Market of the London Stock Exchange. The Mississauga-based YM will use the proceeds to expand and accelerate its product pipeline and commercial focus. The firm was formed to acquire the rights to…